Drugs in Dev. Infections and Infectious Diseases
Phase II/ Phase III
India 
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India
Details : After obtaining the requisite clearance from the Central Drugs Laboratory, Dr. Reddy's Laboratories and RDIF have begun adaptive phase 2/3 clinical trials for the Sputnik V vaccine in India. The trial is a multicenter and randomised controlled safety and...
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Interferon Alpha-2b
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 15, 2016
Lead Product(s) : Recombinant Human Interferon Alpha-2b
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Interferon alfa-2b
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 05, 2013
Lead Product(s) : Recombinant Interferon alfa-2b
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Panel May Review Gennova's mrna Omicron Booster Vaccine
Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gennova Biopharma Submits Final Vaccine Trial Data to Regulator
Details : Company has conducted phase-2/3 trials of vaccine candidates to evaluate its safety, immunogenicity and tolerability on 4,000 participants, for first indigenously developed HGCO19, mRNA vaccine for Covid-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 03, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
India's First Homegrown mRNA COVID-19 Vaccine Currently Under Final Clinical Trial Stages: Govt
Details : Gennova's synthetic, self-replicating India's first homegrown mRNA vaccine is in Phase III Clinical Trials for the treatment of COVID-19 is currently under final clinical trial stages. .
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Corbevax is an RBD protein based sub-unit vaccine against the coronavirus infections. Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Covid vaccine: Bio E May submit Corbevax Trial Data This Month
Details : Corbevax is in phase-3 trials and likely to complete all the studies by end of November which is when company is expecting licence. The licence for children should follow one month later.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
